Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors

Cristina L. Ronchi, M. Peracchi, S. Corbetta, S. Massironi, C. Ciafardini, D. Conte, P. Beck-Peccoz, A. Spada

Research output: Contribution to journalArticlepeer-review

Abstract

Previous experiments reported desensitization to SS action in rat anterior pituitary cells and cell lines. The aim of the study was to verify whether the lack of desensitization to SS analogs (SSa) observed in acromegalic patients was also present in subjects with normal hypothalamic-pituitary function. The effect of chronic treatment with octreotide long-acting release (o-LAR, 10-30 mg/28 days) on IGF-I levels was then evaluated in 23 patients with gastroenteropancreatic (GEP) endocrine tumors (8 gastrinomas, 6 carcinoids, and 9 functioning pancreatic tumors). Serum IGF-I, clinical symptoms, plasma chromogranin-A (CgA) and markers of hepatic synthesis were evaluated before and after a short-term period in all the patients (median 4.5 months), after a medium-term period in 12 (median 18 months) and after a long-term follow-up period in 9 of them (median 48 months). Mean IGF-I levels decreased from 17.3±7.0 to 12.8±6.2 nmol/l in the short-term (p

Original languageEnglish
Pages (from-to)241-246
Number of pages6
JournalJournal of Endocrinological Investigation
Volume30
Issue number3
Publication statusPublished - Mar 2007

Keywords

  • GEP endocrine tumors
  • IGF-I
  • SS analogs
  • Tachyphylaxis

ASJC Scopus subject areas

  • Endocrinology

Fingerprint

Dive into the research topics of 'Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors'. Together they form a unique fingerprint.

Cite this